SRDX Valuation

Surmodics Inc

Add to Watchlist

Advanced Chart

26.420

-1.125(-4.084%)1D

SRDX Relative Valuation

SRDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SRDX is overvalued; if below, it's undervalued.

Historical Valuation

Surmodics Inc (SRDX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 27.55 is considered Overvalued compared with the five-year average of -32.48. The fair price of Surmodics Inc (SRDX) is between 7.01 to 10.41 according to relative valuation methord. Compared to the current price of 26.42 USD , Surmodics Inc is Overvalued By 153.71%.

Relative Value

Fair Zone

7.01-10.41

Current Price：26.42

153.71%

Overvalued

-74.45

Trailing

Forward

31.79

EV/EBITDA

Surmodics Inc. (SRDX) has a current EV/EBITDA of 31.79. The 5-year average EV/EBITDA is 18.16. The thresholds are as follows: Strongly Undervalued below -77.03, Undervalued between -77.03 and -29.44, Fairly Valued between 65.75 and -29.44, Overvalued between 65.75 and 113.34, and Strongly Overvalued above 113.34. The current Forward EV/EBITDA of 31.79 falls within the Historic Trend Line -Fairly Valued range.

-52.21

EV/EBIT

Surmodics Inc. (SRDX) has a current EV/EBIT of -52.21. The 5-year average EV/EBIT is -31.90. The thresholds are as follows: Strongly Undervalued below -354.35, Undervalued between -354.35 and -193.13, Fairly Valued between 129.33 and -193.13, Overvalued between 129.33 and 290.55, and Strongly Overvalued above 290.55. The current Forward EV/EBIT of -52.21 falls within the Historic Trend Line -Fairly Valued range.

27.55

Surmodics Inc. (SRDX) has a current PS of 27.55. The 5-year average PS is 4.64. The thresholds are as follows: Strongly Undervalued below 0.21, Undervalued between 0.21 and 2.43, Fairly Valued between 6.86 and 2.43, Overvalued between 6.86 and 9.07, and Strongly Overvalued above 9.07. The current Forward PS of 27.55 falls within the Strongly Overvalued range.

0.00

P/OCF

Surmodics Inc. (SRDX) has a current P/OCF of 0.00. The 5-year average P/OCF is 26.31. The thresholds are as follows: Strongly Undervalued below -188.15, Undervalued between -188.15 and -80.92, Fairly Valued between 133.55 and -80.92, Overvalued between 133.55 and 240.78, and Strongly Overvalued above 240.78. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

428.07

P/FCF

Surmodics Inc. (SRDX) has a current P/FCF of 428.07. The 5-year average P/FCF is -408.56. The thresholds are as follows: Strongly Undervalued below -3925.21, Undervalued between -3925.21 and -2166.88, Fairly Valued between 1349.77 and -2166.88, Overvalued between 1349.77 and 3108.09, and Strongly Overvalued above 3108.09. The current Forward P/FCF of 428.07 falls within the Historic Trend Line -Fairly Valued range.

Surmodics Inc (SRDX) has a current Price-to-Book (P/B) ratio of 3.54. Compared to its 3-year average P/B ratio of 4.02 , the current P/B ratio is approximately -12.00% higher. Relative to its 5-year average P/B ratio of 4.29, the current P/B ratio is about -17.48% higher. Surmodics Inc (SRDX) has a Forward Free Cash Flow (FCF) yield of approximately -0.90%. Compared to its 3-year average FCF yield of -1.09%, the current FCF yield is approximately -17.16% lower. Relative to its 5-year average FCF yield of -0.60% , the current FCF yield is about 51.05% lower.

3.54

P/B

Median3y

4.02

Median5y

4.29

-0.90

FCF Yield

Median3y

-1.09

Median5y

-0.60

Competitors Valuation Multiple

The average P/S ratio for SRDX's competitors is 23.35, providing a benchmark for relative valuation. Surmodics Inc Corp (SRDX) exhibits a P/S ratio of 27.55, which is 17.96% above the industry average. Given its robust revenue growth of -2.55%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Mesa Laboratories Inc

Treace Medical Concepts Inc

Alpha Tau Medical Ltd

3.96

336.77M

Performance Decomposition

Market capitalization of SRDX decreased by 30.18% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -22.18 to -22.21.

The secondary factor is the Revenue Growth, contributed -2.55%to the performance.

Overall, the performance of SRDX in the past 1 year is driven by P/E Change. Which is more unsustainable.

-2.55%

30.34M → 29.57M

Revenue Growth

-27.75%

-24.90 → -17.99

Margin Expansion

0.12%

-22.18 → -22.21

P/E Change

-30.18%